Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Oct 28, 2013; 19(40): 6710-6713
Published online Oct 28, 2013. doi: 10.3748/wjg.v19.i40.6710
Published online Oct 28, 2013. doi: 10.3748/wjg.v19.i40.6710
Clostridium difficile infection in the community: Are proton pump inhibitors to blame?
Daniel E Freedberg, Julian A Abrams, Division of Digestive and Liver Diseases, Columbia University Medical Center, New York, NY 10032, United States
Author contributions: Freedberg DE and Abrams JA contributed equally to this work.
Supported by National Institute of Diabetes and Digestive and Kidney Diseases T32 DK083256-0 to Freedberg DE; a National Cancer Institute Career Development Award K07 CA 132892 to Abrams JA
Correspondence to: Daniel E Freedberg, MD, Division of Digestive and Liver Diseases, Columbia University Medical Center, 630 West 168th Street, PH Bldg Floor 7, New York, NY 10032, United States. def2004@columbia.edu
Telephone: + 1-212-3420238 Fax: +1-212-3425759
Received: August 16, 2013
Revised: September 12, 2013
Accepted: September 15, 2013
Published online: October 28, 2013
Revised: September 12, 2013
Accepted: September 15, 2013
Published online: October 28, 2013
Core Tip
Core tip: Population-based studies demonstrate that non-antibiotic associated, community-acquired Clostridium difficile infection (CDI) is increasingly common. Patients with community-acquired CDI are younger and have fewer comorbidities compared to patients with hospital-associated CDI. Proton pump inhibitors may be a risk factor for non-antibiotic associated, community-acquired CDI.